Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The new palladium catalyst is effective and reusable for making pharmaceutical ingredients.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

A rare case of Cushing's syndrome and pheochromocytoma requires careful re-evaluation to avoid complications.

PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.

Cronkhite-Canada syndrome is a rare condition causing gut polyps, hair loss, skin changes, and nail issues, often with a poor outlook.

Certain genetic markers can indicate a person's risk of developing prostate cancer.

Activating PPAR-γ signalling can protect hair follicle stem cells from damage caused by chemotherapy.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

M50054 may help treat hepatitis and hair loss from chemotherapy.

Different types of skin cells have unique genetic markers that affect how likely they are to spread cancer.

pCLCA2 protein may help maintain skin structure and function.

The -866G/A polymorphism in the UCP2 gene is not linked to polycystic ovary syndrome.

The document concludes that better treatments for CCCA are needed and more research is required to understand its causes related to hairstyling and genetics.

Seven new genetic risk areas for prostate cancer were found.

Skin tumor cells in patients with tuberous sclerosis have higher levels of a protein called cathepsin B.

Transcutaneous vaccination using nanoparticles can enhance immune responses and reduce basal cell carcinomas.

Two patients with Cronkhite-Canada syndrome achieved remission after treatment.

A rare gene variant causes sexual development issues in siblings, needing personalized treatment.

Blocking S100A8 can reduce chemotherapy-induced hair loss.

A new genetic mutation causing Xeroderma Pigmentosum was found in an 8-year-old girl, affecting her DNA repair.

CXCR2 in skin cells promotes tumor growth.

The PON1 192R gene variant is linked to a higher risk of psoriasis and heart disease in Western Mexico.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Similar treatments might work for different types of scarring hair loss.

Certain genetic changes in the LSS gene cause a rare skin and hair condition.